Ionis Pharmaceuticals IONS Number of reportable segments
Number of reportable segments at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NumberOfReportableSegments.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's number of reportable segments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's number of reportable segments?
- Ionis Pharmaceuticals (IONS) reported number of reportable segments of 1 in Q1 2026.
- How has Ionis Pharmaceuticals's number of reportable segments changed year-over-year?
- Ionis Pharmaceuticals's number of reportable segments increased by 300.0% year-over-year, from 0.3 to 1.
- What does number of reportable segments mean?
- The number of business segments that meet the criteria for mandatory disclosure in financial reports.
- How do you interpret number of reportable segments?
- A higher number indicates a more diversified business model with multiple significant revenue or cost centers, whereas a lower number suggests a highly integrated or singular business focus.
- How does number of reportable segments compare across companies?
- Most specialized pharmaceutical firms report as a single segment due to the integrated nature of their R&D and commercialization pipelines, making this a key indicator of business scope.